CREATING
HIGH QUALITY
PHARMACEUTICAL
PRODUCTS

CREATING
HIGH QUALITY
PHARMACEUTICAL
PRODUCTS

Haixi is incorporated in Victoria, Australia, and is the holding company of the Group. The main operating entity of the Group, Fujian Yong’an Pharmaceutical Co., Ltd (Yong’an or Haixi China), was established in December 1995 and is headquartered in Fujian, China.

It is engaged in the manufacturing, sales, and R&D of pharmaceutical medicinal products. Its products include over the counter ointment and medicinal creams to treat pain, swelling and itching, as well as orally ingestible tablets, capsules and liquids. Haixi China’s brand is long-standing, highly recognised and respected in the pharmaceutical industry in China.

Haixi is incorporated in Victoria, Australia, and is the holding company of the Group. The main operating entity of the Group, Fujian Yong’an Pharmaceutical Co., Ltd (Yong’an or Haixi China), was established in December 1995 and is headquartered in Fujian, China.

It is engaged in the manufacturing, sales, and R&D of pharmaceutical medicinal products. Its products include over the counter ointment and medicinal creams to treat pain, swelling and itching, as well as orally ingestible tablets, capsules and liquids. Haixi China’s brand is long-standing, highly recognised and respected in the pharmaceutical industry in China.

Haixi China has a dedicated management team with many years of experience and co-founders who are actively involved in the day-to-day management of the Group. Haixi China operates within a strongly regulated industry sector of significant scale and with access to capital markets. Haixi China has the potential for significant future growth, both organically and through vertical and horizontal integrations.

Haixi China has approximately over 50,000 square metres of facilities, offices and factories in Yong'an City, China.

In June 2013, Haixi China received government approvals from the Yong'an City Planning Bureau to expand its factory complex by 70,000 square metres. After expansion, the factory is estimated to have a market value of approximately A$20 million.

As of the date of this Prospectus, Haixi China has 99 employees, including 14 senior management officers and 85 production and operational staff.

Haixi China adopts strong management systems and operates fully in accordance with its Articles of Association. The board of directors are selected by the shareholders and possess a skills matrix that is crucial to Haixi China's development. The management team, who are accountable to the board, are responsible for the day to day operations and communication with each of Haixi China's departments. Clear communication channels have been established between each department to ensure efficiency in production processes and high quality products.

The Company was incorporated in Victoria on 13 January 2017. A group restructure, commencing in January 2017, and completing in April 2017, resulted in:

  • the acquisition of Yong'an Pharmaceutical Investment Co., Ltd (Haixi HK) by the Company, which is a company incorporated in Hong Kong;
  • the acquisition of a wholly foreign-owned enterprise, Yong'an Tongtai Pharmaceutical Co., Ltd (WFOE), by Haixi HK; and
  • the acquisition by Haixi of 100% of the capital in Haixi China.

The Group structure is shown in the diagram below.